Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease
Rahul Shah(The University of Texas MD Anderson Cancer Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Reena Jayani(Vanderbilt University Medical Center), James H. Jerkins(Vanderbilt University Medical Center), Olalekan O. Oluwole(Vanderbilt University), Danielle Murphy(Rush University Medical Center), Melissa Logue(Vanderbilt University Medical Center), Carrie L. Kitko(Vanderbilt University Medical Center), Wichai Chinratanalab(VA Tennessee Valley Healthcare System), Kassim Adetola(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Bipin N. Savani(Vanderbilt University Medical Center), Andrew Jallouk(Vanderbilt University Medical Center), Tae Kyoung Kim(University Health Network), Eden Biltibo(Vanderbilt University Medical Center)
Cited by 18
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k